Advanced drug delivery systems incorporating exogenous albumin might have the potential to ameliorate the drawbacks of hypoalbuminaemia and drug-drug interactions on the pharmacokinetics of pharmaceutical agents that bind to endogenous albumin (Vishnu and Roy, 2011; Larsen et al., 2016; Hassanin and Elzoghby, 2020; Spada et al., 2021). This evidence concerns the gene ALB and Hypoalbuminemia.